These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. Wu TH; Hsiue EH; Lee JH; Lin CC; Yang JC Expert Rev Respir Med; 2017 Jan; 11(1):51-55. PubMed ID: 27927060 [TBL] [Abstract][Full Text] [Related]
25. Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients. Scodes S; Cappuzzo F Expert Rev Respir Med; 2020 Jun; 14(6):565-576. PubMed ID: 32233809 [No Abstract] [Full Text] [Related]
26. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. Wu JY; Yu CJ; Shih JY Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643 [TBL] [Abstract][Full Text] [Related]
27. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Kuiper JL; Hashemi SM; Thunnissen E; Snijders PJ; Grünberg K; Bloemena E; Sie D; Postmus PE; Heideman DA; Smit EF Br J Cancer; 2016 Dec; 115(12):1504-1512. PubMed ID: 27875527 [TBL] [Abstract][Full Text] [Related]
28. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation. Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China. Wang Y; Yuan X; Yang M; Shen Z; Chen H; He X; Ma Y; Ding L Pharmacology; 2021; 106(11-12):658-666. PubMed ID: 34673645 [TBL] [Abstract][Full Text] [Related]
30. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. Sehgal K; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB Oncologist; 2021 Apr; 26(4):281-287. PubMed ID: 32969527 [TBL] [Abstract][Full Text] [Related]
31. [Effectiveness of tyrosine kinase inhibitors against non-small cell lung cancer patients with postoperative recurrence harboring uncommon EGFR mutations]. Yang WJ; Gao YB; Qiu T; Wang YG; He J Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):732-736. PubMed ID: 29061015 [No Abstract] [Full Text] [Related]
32. Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis. Mehta A; Vasudevan S Cancer Treat Res Commun; 2021; 28():100398. PubMed ID: 34052672 [TBL] [Abstract][Full Text] [Related]
33. The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations. Watanabe M; Oizumi S; Kiuchi S; Yamada N; Yokouchi H; Fukumoto S; Harada M Intern Med; 2018 Apr; 57(7):993-996. PubMed ID: 29225262 [TBL] [Abstract][Full Text] [Related]
34. [Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer]. Yang X; Chen H; Zhang H; Duan J; An T; Zhao J; Zhuo M; Wu M; Wang J Zhongguo Fei Ai Za Zhi; 2015 Aug; 18(8):493-9. PubMed ID: 26302346 [TBL] [Abstract][Full Text] [Related]
35. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Yasuda H; Park E; Yun CH; Sng NJ; Lucena-Araujo AR; Yeo WL; Huberman MS; Cohen DW; Nakayama S; Ishioka K; Yamaguchi N; Hanna M; Oxnard GR; Lathan CS; Moran T; Sequist LV; Chaft JE; Riely GJ; Arcila ME; Soo RA; Meyerson M; Eck MJ; Kobayashi SS; Costa DB Sci Transl Med; 2013 Dec; 5(216):216ra177. PubMed ID: 24353160 [TBL] [Abstract][Full Text] [Related]
36. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy. Sari M; Aydiner A J Cancer Res Ther; 2020; 16(1):132-138. PubMed ID: 32362623 [TBL] [Abstract][Full Text] [Related]
37. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. Chung C J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240 [TBL] [Abstract][Full Text] [Related]
38. The Frequency of Epidermal Growth Factor Receptor (EGFR) mutations in Iraqi patients with Non-Small Cell Lung Cancer (NSCLC). Ramadhan HH; Taaban DF; Hassan JK Asian Pac J Cancer Prev; 2021 Feb; 22(2):591-596. PubMed ID: 33639678 [TBL] [Abstract][Full Text] [Related]
39. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. Watanabe S; Minegishi Y; Yoshizawa H; Maemondo M; Inoue A; Sugawara S; Isobe H; Harada M; Ishii Y; Gemma A; Hagiwara K; Kobayashi K J Thorac Oncol; 2014 Feb; 9(2):189-94. PubMed ID: 24419415 [TBL] [Abstract][Full Text] [Related]
40. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]